Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sickle cell disease
Biotech
Agios says adios to sickle cell program over lackluster data
The phase 2 study of Agios’ next-generation pyruvate kinase activator failed to support continued development in sickle cell disease.
Nick Paul Taylor
Jul 21, 2026 8:30am
Fulcrum scraps SCD plan as FDA takes hard line on safety risks
Jun 2, 2026 8:46am
Agios’ next-gen PK drug fails ph. 2 blood cancer study
May 29, 2026 9:13am
Novo Nordisk readies SCD drug for approval push after ph. 3 win
Apr 20, 2026 8:33am
Inside Beam's 'big push' for in vivo gene editing
Jan 21, 2026 7:52am
Pfizer pulls the plug on 11 programs
Nov 4, 2025 2:40pm
